AstraZeneca Pharma Intrinsic Value
ASTRAZEN Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹2520.00 | ₹2016.00 - ₹3024.00 | -70.0% | EPS: ₹79.70, Sector P/E: 22x |
| Book Value Method | asset | ₹3080.00 | ₹2772.00 - ₹3388.00 | -63.3% | Book Value/Share: ₹1540.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹8192.00 | ₹7372.80 - ₹9011.20 | -2.5% | Revenue/Share: ₹4096.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹6320.00 | ₹5688.00 - ₹6952.00 | -24.8% | EBITDA: ₹316.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹3360.00 | ₹2688.00 - ₹4032.00 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹2520.00 | ₹2268.00 - ₹2772.00 | -70.0% | EPS Growth: 20.0%, Fair P/E: 16.0x |
| Growth Adjusted P/E | growth | ₹2520.00 | ₹2268.00 - ₹2772.00 | -70.0% | Revenue Growth: 15.0%, Adj P/E: 16.1x |
| ROE Based Valuation | profitability | ₹6368.00 | ₹5731.20 - ₹7004.80 | -24.2% | ROE: 25.8%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹2520.00 | ₹2268.00 - ₹2772.00 | -70.0% | EPS: ₹79.70, BVPS: ₹1540.00 |
Want to compare with current market value? Check ASTRAZEN share price latest .
Valuation Comparison Chart
ASTRAZEN Intrinsic Value Analysis
What is the intrinsic value of ASTRAZEN?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of AstraZeneca Pharma (ASTRAZEN) is ₹3080.00 (median value). With the current market price of ₹8400.00, this represents a -63.3% variance from our estimated fair value.
The valuation range spans from ₹2520.00 to ₹8192.00, indicating ₹2520.00 - ₹8192.00.
Is ASTRAZEN undervalued or overvalued?
Based on our multi-method analysis, AstraZeneca Pharma (ASTRAZEN) appears to be trading above calculated value by approximately 63.3%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 29.82 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.97 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 25.8% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 14.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.35x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
Related Pages for AstraZeneca Pharma
Additional stock information and data for ASTRAZEN
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹65 Cr | ₹65 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹28 Cr | ₹28 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹58 Cr | ₹58 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹101 Cr | ₹101 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹105 Cr | ₹105 Cr | Positive Free Cash Flow | 8/10 |